TICKERNERD
Menu
PLXPLXHealthcare · Biotechnology

PLX Stock Forecast: Protalix Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$2.69
−0.37% on the day

The 1 Wall Street analysts covering Protalix Biotherapeutics, Inc. hold a median 12-month price target of $11 — +308.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$216.7M
Ticker Nerd rank
89 / 100
Median analyst target
$11
Analysts covering
1
Revenue$19.9M+27.1% y/y
Operating income$4.7M
Net income$3.8M
Free cash flow−$11.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.9%
1M
+15.0%
YTD
+49.4%
1Y
+44.6%
From 52W high
−14.6%
From 52W low
+61.1%
$1.67
$3.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PLX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Protalix Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
98
Growth
81
Momentum
77
Volatility
77
Revisions
69
Size
67
Issuance
29
Accruals
14

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26PLXHigh $12Median $11Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $10Median $11High $12

The green dot is the last close — the median target sits +308.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
21 Nov 2025HC Wainwright & Co.MaintainsBuy—
3 Feb 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
31 Oct 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PLX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Protalix Biotherapeutics, Inc. returned +44.6% against +16.3% for the S&P 500, dividends included.

PLX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26PLXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+23.1%
Analysts raising
1
Analysts cutting
0
Fundamentals

Protalix Biotherapeutics, Inc. (PLX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.7×

Cheaper than 54% of US stocks

Price / sales
2.7×

Cheaper than 45% of US stocks

Price / book
3.0×

Cheaper than 32% of US stocks

EV / EBITDA
7.5×

Cheaper than 47% of US stocks

Growth & margins
Revenue growth (YoY)
27.1%

Higher than 76% of US stocks

Earnings growth (YoY)
2203.0%

Higher than 99% of US stocks

Gross margin
61.0%

Higher than 74% of US stocks

Operating margin
23.5%

Higher than 83% of US stocks

Net margin
23.5%

Higher than 85% of US stocks

Returns & dividend
Return on equity
31.2%

Higher than 88% of US stocks

Return on assets
15.4%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Protalix Biotherapeutics, Inc. (PLX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Protalix Biotherapeutics, Inc. has a market value of $216.7M and an enterprise value of $185.3M.

  • Revenue in the twelve months to 30 June 2026: $80.6M. The latest quarter grew 27.1% year on year.

  • Net income over the same four quarters: $18.9M, a 23.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $7.7M.

  • Shares outstanding: 80.6M.

  • Trailing P/E: 11.7×; forward P/E: 4.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Protalix Biotherapeutics, Inc. employs 226 people — $357K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

PLX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLXProtalix Biotherapeutics, Inc.$216.7M
89
VRXAVERAXA Biotech AG$215.7M
20
KROSKeros Therapeutics, Inc.$220.6M
71
ELDNEledon Pharmaceuticals, Inc.$212.9M
35
IVVDInvivyd, Inc.$222.5M
21
TARAProtara Therapeutics, Inc.$209.8M
36
AVXLAnavex Life Sciences Corp.$224.3M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Protalix Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLX news & analysis

Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Protalix BioTherapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published on Seeking Alpha. The item reports on the company's conference participation and presentation content.

Why it matters — PLX watchers would care because the conference presentation offers insight into the company's current positioning and communications with the investment community.

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

PRNewsWire · 8 Sept 2026neutral

Protalix BioTherapeutics announced that its Senior Vice President and Chief Financial Officer, Gilad Mamlok, is scheduled to participate in two upcoming investor conferences in New York City in September 2026. The announcement was made on September 8, 2026.

Why it matters — PLX watchers would care because the company's CFO will be presenting at investor conferences, offering an opportunity for the company to communicate its business to the investment community.

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Seeking Alpha published a transcript of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call, covering the company's second-quarter results for that period.

Why it matters — A PLX watcher would care because the earnings call transcript provides direct insights into the company's Q2 2026 financial performance and management commentary.

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

PRNewsWire · 12 Aug 2026positive

Protalix BioTherapeutics reported second quarter 2026 financial results, with product sales of Elfabrio driving revenue up to $19.8 million for the quarter and $53.6 million year-to-date, including a previously reported $25.0 million Chiesi milestone payment. The company achieved year-to-date profitability with net income of $22.1 million, reiterated full-year 2026 revenue guidance of $78.0-83.0 million, and noted that its PRX-115 Phase 2 study is advancing as planned with top-line results expected in the second half of 2027.

Why it matters — The results show revenue growth, year-to-date profitability, maintained guidance, and an on-track PRX-115 development program, key indicators for PLX watchers.

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

PRNewsWire · 5 Aug 2026neutral

Protalix BioTherapeutics announced it will release its second quarter 2026 financial results and provide a business update on August 12, 2026, followed by a conference call and webcast at 8:00 a.m. EDT.

Why it matters — PLX watchers will be interested in the financial results and business update for the quarter ended June 30, 2026, as they provide insight into the company's recent performance and progress.

FAQ

Frequently asked questions about PLX stock

What is the PLX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Protalix Biotherapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLX stock a buy right now?

Of the 1 analysts covering Protalix Biotherapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protalix Biotherapeutics, Inc. 89 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLX?

As at 19 Sept 2026, Protalix Biotherapeutics, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will PLX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +308.9% from the last close, and Ticker Nerd's factor model ranks Protalix Biotherapeutics, Inc. 89 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLX stock forecast for 2030?

No analyst covering Protalix Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $12 over the next 12 months.

How has PLX stock performed over the past year?

Protalix Biotherapeutics, Inc. returned +44.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Protalix Biotherapeutics, Inc. do?

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system.

What is the latest news on PLX?

The most recent item we track (Seeking Alpha, 16 Sept 2026): "Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Protalix BioTherapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published on Seeking Alpha. The item reports on the company's conference participation and presentation content.

Company

About Protalix Biotherapeutics, Inc.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company’s current portfolio centers on treatments for rare diseases, including Elelyso for Gaucher disease and Elfabrio for adult patients with Fabry disease. Protalix also advances a pipeline of plant cell-expressed candidates such as PRX-115 for gout and PRX-119 for NETs-related diseases, reflecting its emphasis on enzyme replacement therapies and other biologic approaches for conditions with limited treatment options. Based in Karmiel, Israel, Protalix serves global markets through product commercialization and partnership-based development across its specialty biopharmaceutical programs.

CEO Mr. Dror Bashan · 226 employees · United States · https://www.protalix.com